Response by SuperOme
GLP-1 weight program

Response by SuperOme

Proteomic Response Report · Clinician edition

How this patient's biology responded to 12 weeks of semaglutide.

About 1,000 plasma proteins measured at four timepoints on one plate, read against the patient's own baseline noise, and anchored to accredited clinical chemistry.

Participant
M.K. · R-0417 · 52 F
Program
GLP-1 initiation (semaglutide)
Indication
Weight management, prediabetes (HbA1c 6.1%)
Ordering clinician
Dr. A. RiveraMeridian Longevity Clinic, Austin TX
Timepoints
Baseline · Week 4 · Week 8 · Week 12
Collection
Home capillary dried blood, 4 samples returned together
Platform
Multiplex proteomics panel v2.1 (pg/mL)
Report date
12 Jun 2026

Research Use Only. Proteomic results are not a diagnosis; accredited clinical chemistry values are the only results on which clinical action should be taken.

Response by SuperOmeAt a glance

M.K. · R-0417 · GLP-1 initiation (semaglutide)

Three things to know before the next visit.

Improved

Metabolic, inflammatory, hepatic and endothelial markers moved together and agree with the clinic HbA1c, ALT, lipids and hs-CRP.

Unchanged

No kidney or neuro marker left the patient's own noise band. Reported as a result, not an omission.

Review with the patient

A muscle/bone pattern consistent with lean-mass loss, and a gut-epithelial marker that rose during the nausea weeks. Neither is diagnostic.

Metabolic & GLP-1 axis12
Inflammation10
Liver8
Cardiovascular & endothelium9
Kidney6
Muscle & bone11
Gut barrier & mucosa7
Brain & neuro5
1.5× noise band · shaded = unchanged zoneproteins
Each bar is the mean shift of an organ system’s proteins, in multiples of this patient’s own within-person noise, signed so that right = favourable. Bars inside the shaded zone are indistinguishable from no change. This is not a biological age and is not comparable across patients.

Proteins in this report

68

in curated organ panels.

Status split

21
improved
41
unchanged
5
review
1
below quantification

Next window

Week 16–18, after 4+ weeks at a stable dose. Re-check muscle/bone and gut panels; consider DXA before the next dose step.

Reading rule. Teal = moved in the direction the program intends. Stone = did not move beyond this patient’s own noise. Amber = moved in a direction worth a conversation. A protein is never flagged on a population reference range alone; the comparison is always to the patient’s own baseline.

Response by SuperOme Proteomic Response Report · Clinician editionResearch Use OnlyPage 2 of 13

Response by SuperOmeClinical anchors

M.K. · R-0417

Accredited laboratory values and program context.

Venous draws in clinic at Baseline and Week 12, run by a CLIA-accredited laboratory. These are the values on which clinical decisions should rest. The proteomic panels that follow are read against them.

  • Weight

    Improved

    91.4 → 83.7 kg · −8%

  • BMI

    Improved

    33.1 → 30.3 kg/m² · −8%

  • HbA1c

    Improved

    6.1 → 5.6 % · −8% · reference < 5.7

  • Fasting glucose

    Improved

    108 → 94.0 mg/dL · −13% · reference 70–99

  • Fasting insulin

    Improved

    17.8 → 10.2 µIU/mL · −43% · reference 2.6–24.9

  • ALT

    Improved

    38.0 → 27.0 U/L · −29% · reference 7–35

  • AST

    Improved

    31.0 → 26.0 U/L · −16% · reference 8–33

  • Lipase

    Review

    31.0 → 36.0 U/L · +16% · reference 13–60

  • Creatinine

    Unchanged

    0.82 → 0.84 mg/dL · +2% · reference 0.57–1.00

  • eGFR (CKD-EPI 2021)

    Unchanged

    88.0 → 86.0 mL/min/1.73m² · −2% · reference > 60

  • LDL-C

    Improved

    131 → 112 mg/dL · −15% · reference < 100

  • ApoB

    Improved

    104 → 89.0 mg/dL · −14% · reference < 90

  • Triglycerides

    Improved

    168 → 121 mg/dL · −28% · reference < 150

  • hs-CRP

    Improved

    3.6 → 1.8 mg/L · −50% · reference < 1.0 low risk

  • hs-cTnI

    Unchanged

    < 3 → < 3 ng/L · reference < 16

  • NT-proBNP

    Unchanged

    42.0 → 38.0 pg/mL · −10% · reference < 125

  • Grip strength (dominant)

    Review

    26.0 → 24.0 kg · −8% · reference ≥ 20 (F)

Weight

91.4Baseline88.9Week 486.1Week 883.7Week 12

Dose schedule

  1. 0.25 mg from week 0 to week 4
  2. 0.5 mg from week 4 to week 8
  3. 1.0 mg from week 8 to week 12

Weekly subcutaneous. Adherence 12/12 injections logged.

Reported effects

Reported effects
Wk 1–2Mild nausea after injection daymild
Wk 3–6Nausea most days; two episodes of vomiting (wk 5, dose step)notable
Wk 7–9Constipation; resolved with fibre + fluidsmild
Wk 10–12No GI symptoms reported; early satiety onlyresolved

Lipase rose within the reference interval (31 → 36 U/L). No abdominal pain reported. Noted because pancreatitis is the threshold alarm on this drug class; no action implied.

hs-cTnI and NT-proBNP are reported from the accredited lab, not from the proteomic panel. Affinity proteomics does not deliver clinical-grade troponin quantification.

Response by SuperOme Proteomic Response Report · Clinician editionResearch Use OnlyPage 3 of 13

Response by SuperOmeMetabolic & GLP-1 axis

M.K. · R-0417 · GLP-1 initiation (semaglutide)

Metabolic & GLP-1 axis

Insulin demand fell, adipokines moved toward a leaner profile, and appetite hormones shifted in the direction expected on a GLP-1. This is the clearest response in the report and is concordant with the clinic HbA1c and fasting glucose.

System verdict

Improved

Organ response index +2.8× noise band · 12 proteins · 10 moved / 2 unchanged / 0 review

  • INS InsulinFasting insulin; concordant with clinic value

    Improved

    640 → 370 pg/mL · −42% · 3.0× noise

  • C-peptide Connecting peptide (C-peptide)

    Improved

    2.9 → 1.9 ng/mL · −34% · 2.9× noise

  • Pro-insulin Pro-insulinPro-insulin:insulin ratio also fell

    Improved

    210 → 125 pg/mL · −40% · 2.7× noise

  • LEP LeptinTracks fat-mass loss

    Improved

    28.4 → 17.1 ng/mL · −40% · 3.6× noise

  • ADIPOQ Adiponectin

    Improved

    6.1 → 7.9 µg/mL · +30% · 3.3× noise

  • FGF21 Fibroblast growth factor 21

    Improved

    312 → 188 pg/mL · −40% · 2.2× noise

  • FABP4 Fatty acid-binding protein, adipocyteAdipocyte-derived

    Improved

    27.8 → 19.2 ng/mL · −31% · 2.6× noise

  • IGFBP1 Insulin-like growth factor-binding protein 1Rises as insulin falls

    Improved

    12.1 → 23.6 ng/mL · +95% · 5.9× noise

  • IGFBP2 Insulin-like growth factor-binding protein 2

    Improved

    181 → 262 ng/mL · +45% · 3.4× noise

  • RBP4 Retinol-binding protein 4

    Unchanged

    31.6 → 27.4 µg/mL · −13% · 1.3× noise

  • GHRL Appetite-regulating hormoneRises with weight loss; expected

    Improved

    618 → 790 pg/mL · +28% · 1.9× noise

  • PYY Peptide YY

    Unchanged

    96.0 → 114 pg/mL · +19% · 1.1× noise

Trajectory shows Baseline → Week 4 → Week 8 → Week 12. “Vs noise” is the Week 12 change divided by this patient’s expected within-person variation for that protein. Changes under 1.5× are reported as unchanged. The noise is the technical replicates on the same plate plus cohort within-person variance. Concentrations are calibrant-relative values from dried capillary blood and are not interchangeable with venous clinical assays of the same analyte.

Response by SuperOme Proteomic Response Report · Clinician editionResearch Use OnlyPage 4 of 13

Response by SuperOmeInflammation

M.K. · R-0417 · GLP-1 initiation (semaglutide)

Inflammation

Acute-phase and adipose-linked inflammation fell. TNF, CCL2 and GDF15 did not move beyond this participant's own noise band; GDF15 is worth re-checking at the next window because it rises on several metabolic drugs.

System verdict

Improved

Organ response index +1.1× noise band · 10 proteins · 5 moved / 5 unchanged / 0 review

  • CRP C-reactive proteinConcordant with clinic hs-CRP

    Improved

    3.8 → 1.9 mg/L · −50% · 2.5× noise

  • SAA1 Serum amyloid A-1 protein

    Improved

    6.2 → 3.1 µg/mL · −50% · 2.3× noise

  • IL6 Interleukin-6

    Improved

    3.1 → 2.0 pg/mL · −35% · 1.9× noise

  • IL1RN Interleukin-1 receptor antagonist proteinIL-1 receptor antagonist

    Improved

    420 → 290 pg/mL · −31% · 2.2× noise

  • S100A9 Protein S100-A9Calprotectin subunit

    Improved

    1,120 → 790 ng/mL · −29% · 1.8× noise

  • TNF Tumor necrosis factor alpha

    Unchanged

    1.9 → 1.8 pg/mL · −5% · 0.4× noise

  • CCL2 C-C motif chemokine 2

    Unchanged

    240 → 226 pg/mL · −6% · 0.4× noise

  • IL18 Interleukin-18

    Unchanged

    241 → 232 pg/mL · −4% · 0.3× noise

  • CXCL8 Interleukin-8

    Unchanged

    6.0 → 5.7 pg/mL · −5% · 0.3× noise

  • GDF15 Growth/differentiation factor 15Monitor; drug-associated rise is common

    Unchanged

    890 → 985 pg/mL · +11% · 1.1× noise

Trajectory shows Baseline → Week 4 → Week 8 → Week 12. “Vs noise” is the Week 12 change divided by this patient’s expected within-person variation for that protein. Changes under 1.5× are reported as unchanged. The noise is the technical replicates on the same plate plus cohort within-person variance. Concentrations are calibrant-relative values from dried capillary blood and are not interchangeable with venous clinical assays of the same analyte.

Response by SuperOme Proteomic Response Report · Clinician editionResearch Use OnlyPage 5 of 13

Response by SuperOmeLiver

M.K. · R-0417 · GLP-1 initiation (semaglutide)

Liver

Hepatocyte-derived markers moved toward lower liver fat and lower transaminase release, in step with the accredited ALT/AST. Fibrosis-associated markers did not change, which is the expected result over 12 weeks.

System verdict

Improved

Organ response index +1.2× noise band · 8 proteins · 4 moved / 4 unchanged / 0 review

  • GPT Alanine aminotransferase 1ALT protein; clinic ALT 38 → 27 U/L

    Improved

    1.9 → 1.3 ng/mL · −32% · 2.4× noise

  • GOT1 Aspartate aminotransferase, cytoplasmicAST protein

    Improved

    2.4 → 1.9 ng/mL · −21% · 1.7× noise

  • FABP1 Fatty acid-binding protein, liverLiver fatty-acid binding protein

    Improved

    18.2 → 11.9 ng/mL · −35% · 2.3× noise

  • FGF19 Fibroblast growth factor 19

    Improved

    112 → 151 pg/mL · +35% · 1.7× noise

  • HGF Hepatocyte growth factor

    Unchanged

    620 → 540 pg/mL · −13% · 0.9× noise

  • TIMP1 Metalloproteinase inhibitor 1Fibrosis-associated

    Unchanged

    151 → 143 ng/mL · −5% · 0.6× noise

  • SERPINA1 Alpha-1-antitrypsin

    Unchanged

    1.42 → 1.39 mg/mL · −2% · 0.3× noise

  • AFP Alpha-fetoprotein

    Unchanged

    2.1 → 2.2 ng/mL · +5% · 0.5× noise

Trajectory shows Baseline → Week 4 → Week 8 → Week 12. “Vs noise” is the Week 12 change divided by this patient’s expected within-person variation for that protein. Changes under 1.5× are reported as unchanged. The noise is the technical replicates on the same plate plus cohort within-person variance. Concentrations are calibrant-relative values from dried capillary blood and are not interchangeable with venous clinical assays of the same analyte.

Response by SuperOme Proteomic Response Report · Clinician editionResearch Use OnlyPage 6 of 13

Response by SuperOmeCardiovascular & endothelium

M.K. · R-0417 · GLP-1 initiation (semaglutide)

Cardiovascular & endothelium

Endothelial activation markers fell; PCSK9 and natriuretic peptide drifted down but stayed inside the noise band. Cardiac troponin T is below quantification at every timepoint, which is normal in a healthy heart; it is not a negative result and is not a substitute for a clinical hs-cTnI.

System verdict

Improved

Organ response index +1.2× noise band · 9 proteins · 2 moved / 6 unchanged / 0 review / 1 below LLOQ

  • SELE E-selectinE-selectin

    Improved

    42.0 → 31.0 ng/mL · −26% · 2.2× noise

  • VCAM1 Vascular cell adhesion protein 1

    Unchanged

    612 → 538 ng/mL · −12% · 1.3× noise

  • ICAM1 Intercellular adhesion molecule 1

    Improved

    241 → 206 ng/mL · −15% · 1.6× noise

  • MPO Myeloperoxidase

    Unchanged

    61.0 → 48.0 ng/mL · −21% · 1.3× noise

  • PCSK9 Proprotein convertase subtilisin/kexin type 9Clinic LDL 131 → 112 mg/dL

    Unchanged

    281 → 249 ng/mL · −11% · 1.1× noise

  • APOA1 Apolipoprotein A-I

    Unchanged

    1.31 → 1.36 mg/mL · +4% · 0.6× noise

  • ANGPT2 Angiopoietin-2

    Unchanged

    2.1 → 1.9 ng/mL · −10% · 0.7× noise

  • NPPB Natriuretic peptides BTotal BNP-gene product, not NT-proBNP

    Unchanged

    28.0 → 25.0 pg/mL · −11% · 0.7× noise

  • TNNT2 Troponin T, cardiac muscleBelow LLOQ at all four timepoints

    Below LLOQ

    < 5 → < 5 pg/mL

Trajectory shows Baseline → Week 4 → Week 8 → Week 12. “Vs noise” is the Week 12 change divided by this patient’s expected within-person variation for that protein. Changes under 1.5× are reported as unchanged. The noise is the technical replicates on the same plate plus cohort within-person variance. Concentrations are calibrant-relative values from dried capillary blood and are not interchangeable with venous clinical assays of the same analyte.

Response by SuperOme Proteomic Response Report · Clinician editionResearch Use OnlyPage 7 of 13

Response by SuperOmeKidney

M.K. · R-0417 · GLP-1 initiation (semaglutide)

Kidney

No kidney marker moved outside this participant's own noise band. On a GLP-1 with rapid weight loss, an unchanged kidney panel is the result you want to see; it is reported here as explicitly unchanged rather than omitted.

System verdict

Unchanged

Organ response index 0.0× noise band · 6 proteins · 0 moved / 6 unchanged / 0 review

  • CST3 Cystatin-CCalibrant-relative; not IFCC-traceable

    Unchanged

    0.86 → 0.88 mg/L · +2% · 0.3× noise

  • HAVCR1 Hepatitis A virus cellular receptor 1KIM-1, tubular injury

    Unchanged

    95.0 → 102 pg/mL · +7% · 0.5× noise

  • CLU Clusterin

    Unchanged

    118 → 121 µg/mL · +3% · 0.3× noise

  • SPP1 OsteopontinOsteopontin

    Unchanged

    38.0 → 34.0 ng/mL · −11% · 0.8× noise

  • TIMP2 Metalloproteinase inhibitor 2

    Unchanged

    84.0 → 86.0 ng/mL · +2% · 0.3× noise

  • EGF Pro-epidermal growth factor

    Unchanged

    410 → 430 pg/mL · +5% · 0.4× noise

Trajectory shows Baseline → Week 4 → Week 8 → Week 12. “Vs noise” is the Week 12 change divided by this patient’s expected within-person variation for that protein. Changes under 1.5× are reported as unchanged. The noise is the technical replicates on the same plate plus cohort within-person variance. Concentrations are calibrant-relative values from dried capillary blood and are not interchangeable with venous clinical assays of the same analyte.

Response by SuperOme Proteomic Response Report · Clinician editionResearch Use OnlyPage 8 of 13

Response by SuperOmeMuscle & bone

M.K. · R-0417 · GLP-1 initiation (semaglutide)

Muscle & bone

This is the panel to discuss. IGF-1 fell, follistatin-like 3 rose and two bone-turnover markers rose, a pattern consistent with reduced lean mass or reduced mechanical loading during rapid weight loss. The clinic grip-strength value also dropped. None of this is diagnostic; it is a reason to measure body composition before the next dose step.

System verdict

Review

Organ response index −0.9× noise band · 11 proteins · 0 moved / 7 unchanged / 4 review

  • IGF1 Insulin-like growth factor 1Clinic grip strength 26 → 24 kg

    Review

    142 → 118 ng/mL · −17% · 1.9× noise

  • IGFBP3 Insulin-like growth factor-binding protein 3

    Unchanged

    3.8 → 3.4 µg/mL · −11% · 1.3× noise

  • FSTL3 Follistatin-related protein 3Rises with catabolic signalling

    Review

    9.8 → 12.4 ng/mL · +27% · 2.4× noise

  • CKM Creatine kinase M-typeMuscle-leak protein; also falls with less training

    Unchanged

    120 → 96.0 ng/mL · −20% · 0.9× noise

  • MB Myoglobin

    Unchanged

    32.0 → 29.0 ng/mL · −9% · 0.5× noise

  • FABP3 Fatty acid-binding protein, heart

    Unchanged

    2.1 → 2.0 ng/mL · −5% · 0.3× noise

  • GDF11 Growth/differentiation factor 11

    Unchanged

    168 → 171 pg/mL · +2% · 0.1× noise

  • SOST SclerostinSclerostin; rises with unloading

    Review

    380 → 462 pg/mL · +22% · 1.8× noise

  • ACP5 Tartrate-resistant acid phosphatase type 5TRAP5b, bone resorption

    Review

    2.8 → 3.4 ng/mL · +21% · 1.6× noise

  • TNFRSF11B Tumor necrosis factor receptor superfamily member 11BOsteoprotegerin

    Unchanged

    4,200 → 4,380 pg/mL · +4% · 0.4× noise

  • PTH Parathyroid hormone

    Unchanged

    42.0 → 47.0 pg/mL · +12% · 0.7× noise

Trajectory shows Baseline → Week 4 → Week 8 → Week 12. “Vs noise” is the Week 12 change divided by this patient’s expected within-person variation for that protein. Changes under 1.5× are reported as unchanged. The noise is the technical replicates on the same plate plus cohort within-person variance. Concentrations are calibrant-relative values from dried capillary blood and are not interchangeable with venous clinical assays of the same analyte.

Response by SuperOme Proteomic Response Report · Clinician editionResearch Use OnlyPage 9 of 13

Response by SuperOmeGut barrier & mucosa

M.K. · R-0417 · GLP-1 initiation (semaglutide)

Gut barrier & mucosa

Intestinal fatty-acid binding protein rose during the weeks nausea was reported and had not fully settled by Week 12. Endotoxin-exposure markers drifted down but stayed inside the noise band. Worth re-checking after the dose has been stable for four weeks.

System verdict

Review

Organ response index −0.1× noise band · 7 proteins · 0 moved / 6 unchanged / 1 review

  • FABP2 Fatty acid-binding protein, intestinalI-FABP; enterocyte turnover

    Review

    1.4 → 1.9 ng/mL · +36% · 2.2× noise

  • LBP Lipopolysaccharide-binding protein

    Unchanged

    8.2 → 7.1 µg/mL · −13% · 1.2× noise

  • CD14 Monocyte differentiation antigen CD14Soluble CD14

    Unchanged

    1.62 → 1.51 µg/mL · −7% · 0.8× noise

  • REG3A Regenerating islet-derived protein 3-alphaMucosal repair / antimicrobial

    Unchanged

    60.0 → 72.0 ng/mL · +20% · 1.2× noise

  • REG1B Lithostathine-1-beta

    Unchanged

    18.0 → 21.0 ng/mL · +17% · 0.9× noise

  • TFF3 Trefoil factor 3

    Unchanged

    12.1 → 12.9 ng/mL · +7% · 0.6× noise

  • REG4 Regenerating islet-derived protein 4

    Unchanged

    3.1 → 3.0 ng/mL · −3% · 0.2× noise

Trajectory shows Baseline → Week 4 → Week 8 → Week 12. “Vs noise” is the Week 12 change divided by this patient’s expected within-person variation for that protein. Changes under 1.5× are reported as unchanged. The noise is the technical replicates on the same plate plus cohort within-person variance. Concentrations are calibrant-relative values from dried capillary blood and are not interchangeable with venous clinical assays of the same analyte.

Response by SuperOme Proteomic Response Report · Clinician editionResearch Use OnlyPage 10 of 13

Response by SuperOmeBrain & neuro

M.K. · R-0417 · GLP-1 initiation (semaglutide)

Brain & neuro

Neuro-injury markers were unchanged. Neurofilament light reads close to the assay's quantification limit in dried capillary blood, so small changes should not be interpreted; BDNF drifted up but stayed inside the noise band.

System verdict

Unchanged

Organ response index +0.4× noise band · 5 proteins · 0 moved / 5 unchanged / 0 review

  • NEFL Neurofilament light polypeptideNear LLOQ; interpret with caution

    Unchanged

    9.2 → 9.0 pg/mL · −2% · 0.1× noise

  • GFAP Glial fibrillary acidic protein

    Unchanged

    85.0 → 82.0 pg/mL · −4% · 0.2× noise

  • BDNF Neurotrophic factor BDNF precursor form

    Unchanged

    22.1 → 25.4 ng/mL · +15% · 1.2× noise

  • GRN ProgranulinProgranulin

    Unchanged

    41.0 → 40.0 ng/mL · −2% · 0.3× noise

  • APOE Apolipoprotein E

    Unchanged

    38.0 → 39.0 µg/mL · +3% · 0.3× noise

Trajectory shows Baseline → Week 4 → Week 8 → Week 12. “Vs noise” is the Week 12 change divided by this patient’s expected within-person variation for that protein. Changes under 1.5× are reported as unchanged. The noise is the technical replicates on the same plate plus cohort within-person variance. Concentrations are calibrant-relative values from dried capillary blood and are not interchangeable with venous clinical assays of the same analyte.

Response by SuperOme Proteomic Response Report · Clinician editionResearch Use OnlyPage 11 of 13

Response by SuperOmeFor the visit

M.K. · R-0417

What to discuss, what to measure next, what this report does not do.

Suggested discussion points

  • Lean mass. IGF-1 down 17%, FSTL3 up 27%, sclerostin and TRAP5b up, grip strength 26 → 24 kg, 7.7 kg lost in 12 weeks. Consider DXA (or BIA if DXA is unavailable) before stepping to 1.7 mg; protein intake ≥ 1.2 g/kg and resistance training 2–3×/week.
  • Gut epithelium. I-FABP rose during the nausea weeks and had not returned to baseline by Week 12. Re-check once the dose has been stable for four weeks. If GI symptoms return at the next step, this is the marker to watch.
  • Metabolic response is strong. Fasting insulin, C-peptide, leptin, FGF21 and FABP4 all fell; adiponectin and IGFBP-1 rose. HbA1c is now below the prediabetes threshold.
  • GDF15 drifted up but stayed inside the noise band. Common on metabolic drugs; no action, re-measure.

Next measurement window

Week 16–18 · one home sample, after ≥ 4 weeks at a stable dose.

The next sample will be run with this patient's reserved baseline aliquot on the same plate, so the comparison stays within one calibrator lot.

Questions the patient may ask

  • "Is my liver better?" — ALT and liver-fat proteins fell; fibrosis markers were unchanged, which is expected at 12 weeks.
  • "Am I losing muscle?" — The pattern is consistent with it; a scan answers it.
  • "Is my heart OK?" — Endothelial markers improved; troponin and NT-proBNP from the clinic lab are normal.

What this report does not do

It does not diagnose. Proteomic values are Research Use Only. Any result that would change management should be confirmed with an accredited clinical test.

It does not report a biological age. No published proteomic clock is valid on this platform without re-calibration, so none is shown. Organ response indices are within-patient, sign-and-magnitude readouts.

It does not compare patients. Every flag is relative to this patient's own baseline and noise. Population reference intervals are shown only for the accredited clinical values.

Companion. The patient can ask the companion about any line in this report in plain language. The companion explains and prepares questions; it does not change doses. Anything requiring a medical decision is routed back to the ordering clinician.

Response by SuperOme Proteomic Response Report · Clinician editionResearch Use OnlyPage 12 of 13

Response by SuperOmeMethods & appendix

M.K. · R-0417

How this report was produced

Platform
Multiplex proteomics panel v2.1 · about 1,000 assays · quantification against recombinant standard curves (16-point, 4PL) run on a calibration plate the same day.
Specimen
Capillary whole blood, volumetric tips (20 µL), air-dried and stored at room temperature; four samples returned together at Week 12. Eluted per the panel's protocol (150 µL buffer per tip, 1 h, protease inhibitor).
Batching
All four timepoints for this patient on one plate, same bead lot, same calibrator lot, same run. One aliquot per timepoint held in reserve at −80 °C.
Noise band
Per-protein within-person SD estimated from on-plate technical replicates and cohort baseline variance ("borrowed noise"). A change is reported when it exceeds 1.5× that SD; the direction is then compared to the program's intended direction.
Detectability
781 assays were above LLOQ in all four of this patient's samples and are eligible for reporting; 92 were quantifiable in some timepoints only; 190 were below LLOQ throughout (predominantly intracellular proteins, expected in dried capillary blood).
Sample QC
All four samples passed: haemolysis index low (4 / 4), dwell time 1–84 days recorded, reference sample co-shipped and within tolerance.
Regulatory
Research Use Only. Not CLIA-returnable. Clinical anchors from an accredited laboratory.

Largest whole-panel movers outside the curated panels

Of the proteins not shown on the organ pages, these moved most relative to the patient's own noise. Exploratory; included so nothing large is hidden by panel curation. Detect = timepoints above LLOQ.

GeneproteinΔ Wk12Vs noiseDetect
CSF3Granulocyte colony-stimulating factor+42%4.9×3/4
GPR158Metabotropic glycine receptor+47%4.7×3/4
GPX1Glutathione peroxidase 1−47%4.7×4/4
RGMARepulsive guidance molecule A−47%4.1×3/4
HSPA8Heat shock cognate 71 kDa protein−46%3.8×4/4
SULT2A1Sulfotransferase 2A1−47%3.7×3/4
DLK1Protein delta homolog 1+39%3.6×4/4
SOD1Superoxide dismutase [Cu-Zn]−29%3.2×4/4
IL6RInterleukin-6 receptor subunit alpha−25%2.9×4/4
AOC1Diamine oxidase+27%2.6×3/4
TNFRSF25Tumor necrosis factor receptor superfamily member 25−44%2.6×3/4
GZMAGranzyme A−41%2.3×4/4
CEACAM19Cell adhesion molecule CEACAM19−30%2.1×4/4
DBHDopamine beta-hydroxylase+37%2.1×4/4
SDC3Syndecan-3+30%2.0×3/4
FASTumor necrosis factor receptor superfamily member 6+28%2.0×4/4
CLEC5AC-type lectin domain family 5 member A−32%1.9×4/4
SELPP-selectin+22%1.9×3/4
IL7Interleukin-7−26%1.8×4/4
FCGR3ALow affinity immunoglobulin gamma Fc region receptor III-A+34%1.8×4/4

Within-person CV, LLOQ and detectability come from the per-target validation table of the platform. Gene symbols are the assay identifiers of the panel.

Response by SuperOme Proteomic Response Report · Clinician editionResearch Use OnlyPage 13 of 13